Evidence map›Paper›PMID 38858422›Full record

ArticleScientific reports2024

Alpha-Hederin induces incomplete autophagic injury in non-small cell lung cancer by interfering with the lysosomal acidification.

Feng Jin, Xiaomin Jiang, Xiaochen Ni, Shilong Yu, Feng Wu, Xinlin Shi, Defang Mao, Haibo Wang, Qingtong Shi, Yanqing Liu and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Sustainable Extraction ofInternational journal of molecular sciences · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Feng JinDepartment of Respiratory Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China.
Xiaomin JiangInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Xiaochen NiDepartment of Respiratory Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China.
Shilong YuInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Feng WuDepartment of Respiratory Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China.
Xinlin ShiDepartment of Respiratory Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China.
Defang MaoInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Haibo WangInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Qingtong ShiDepartment of Thoracic Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China.
Yanqing LiuInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Qin XuDepartment of Respiratory Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225001, China. gui.qh@163.com.

Funding

National Natural Science Foundation of China 81903850National Natural Science Foundation of China 82274603Postgraduate Research and Practice Innovation Program of Jiangsu Province SJCX22_1832Traditional Chinese Medicine Science and Technology Development Program of Jiangsu YB201992
6 · The paper itself

Abstract

Lung cancer is the most common oncological disease worldwide, with non-small cell lung cancer accounting for approximately 85% of lung cancer cases. α-Hederin is a monodesmosidic triterpenoid saponin isolated from the leaves of Hedera helix L. or Nigella sativa and has been extensively studied for its antitumor activity against a variety of tumor cells. It has been suggested that α-Hederin is a potential regulator of autophagy and has high promise for application. However, the specific mechanism and characteristics of α-Hederin in regulating autophagy are not well understood. In this study, we confirmed the potential of α-Hederin application in lung cancer treatment and comprehensively explored the mechanism and characteristics of α-Hederin in regulating autophagy in lung cancer cells. Our results suggest that α-Hederin is an incomplete autophagy inducer that targets mTOR to activate the classical autophagic pathway, inhibits lysosomal acidification without significantly affecting the processes of autophagosome transport, lysosome biogenesis, autophagosome and lysosome fusion, and finally leads to impaired autophagic flux and triggers autophagic damage in NSCLC.

Indexed as

AutophagyCarcinoma, Non-Small-Cell LungLung NeoplasmsLysosomesOleanolic AcidSaponinsA549 CellsAutophagosomesCell Line, TumorHumansTOR Serine-Threonine Kinasesbeta-hederinOleanolic AcidSaponinsTOR Serine-Threonine KinasesAntitumorIncomplete autophagyLysosomal acidificationNon-small cell lung cancerα-Hederin

Identifiers

PMID38858422
PMCPMC11164981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.